Cat. No.: DAB-0012793
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human regucalcin/SMP30 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | RGN |
| UniProt No. | Q15493 |
| Gene ID | 9104 |
| Gene Description | Regucalcin is a highly conserved, multifunctional protein encoded by the RGN gene on the X chromosome, generally recognized as a calcium binding protein involved in the maintenance of intracellular Ca2+ homeostasis. The protein was independently identified and termed Senescence Marker Protein-30, following the observation in a rat aging model that expression of the protein markedly declined with age in a hormone-independent manner. Regucalcin/SMP30 has since been implicated in the regulatory control of many fundamental biological processes, largely through its role in regulating Ca2+ homeostasis and Ca2+-dependent signal transduction. Research studies also suggest that regucalcin/SMP30 may function as a tumor suppressor in some contexts, while serum levels of regucalcin/SMP30 have also been proposed as potential biomarkers of liver and kidney dysfunction. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
